Get the Stockscreener App
0.00
100.00%
-4.34
After Hours:
4.35
4.35
+
Lumos Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$4.34
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$37.54M
Revenue:
$2.74M
Net Income/Loss:
$-41.38M
P/E Ratio:
0.00
EPS:
-4.71
Net Cash Flow:
$-31.10M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.5756
Lumos Pharma Inc Stock (LUMO) Company Profile
Name
Lumos Pharma Inc
Sector
Industry
Phone
512-215-2630
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare LUMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUMO
Lumos Pharma Inc
|
0.00 | 37.54M | 2.74M | -41.38M | -31.10M | -5.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lumos Pharma Inc Stock (LUMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-21 | Upgrade | Stifel | Hold → Buy |
| Dec-03-20 | Initiated | Cantor Fitzgerald | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-17-20 | Resumed | ROTH Capital | Buy |
| Aug-04-20 | Initiated | H.C. Wainwright | Buy |
Lumos Pharma Inc Stock (LUMO) Latest News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders - The Eastern Progress Online
Lumos Pharma Completes Merger and Delisting Process - TipRanks
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma - The Manila Times
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma - Yahoo Finance
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders - The Eastern Progress Online
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Down 4.1% – Here’s What Happened - Defense World
Lumos Pharma enters into definitive merger agreement with Double Point Ventures to go private via tender offer - substack.com
Global Human Growth Hormones Market to Reach USD 10 Billion by 2030 | DelveInsight - GlobeNewswire
Lumos Pharma Faces Uncertainty as CVRs Risk Expiring Worthless Post-Merger - MSN
LUMOLumos Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 - GlobeNewswire
Lumos Pharma reports sustained growth in PGHD trials - Investing.com
Biopharma deal value, down for year, surges 72% in October - BioWorld Online
Favourable Signals For Lumos Diagnostics Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, OB on Behalf of Shareholders - GlobeNewswire
Private Advisor Group, LLC Acquires Shares in Lumos Pharma Inc - GuruFocus.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ALTR, STAF on Behalf of Shareholders - Marketscreener.com
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Reviews the Merger of STAF, ATSG, GABC and LUMO - AccessWire
$HAREHOLDER ALERT FOR STAF, ATSG, GABC and ALTM: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire
Lumos: Q3 Earnings Snapshot - CT Insider
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, INSI on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO - GlobeNewswire Inc.
Peregrine Gold Ltd Confirms Prospectus Lodgement for Security Issue - MSN
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024 - The Manila Times
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Discover Smart Share Global Among 2 Other Prominent US Penny Stocks - Simply Wall St
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ZUO, ARC on Behalf of Shareholders - Stockhouse Publishing
Analyst Expectations For Lumos Pharma's Future - Benzinga
INVESTIGATION ALERT: Halper Sadeh LLC Continues to - GlobeNewswire
Kuehn Law Encourages MMLP, ICCH, FSHP, and LUMO Investors to Contact Law Firm - Morningstar
DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology
Lumos Pharma to be acquired by Double Point Ventures - Investing.com Canada
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc. - Marketscreener.com
Jones Trading cuts Lumos Pharma shares rating amid Double Point merger - Investing.com UK
Lumos inks take-private deal with Double Point Ventures - MSN
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders - Business Wire
Lumos Pharma Shares Rally After Double Point Deal - MarketWatch
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - The Manila Times
Lumos stock in focus after take-private deal (LUMO:NASDAQ) - Seeking Alpha
Double Point to Buy Lumos Pharma for $38M as FDA OKs Lumos Drug Trial - MarketWatch
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, USAP, SASR on Behalf of Shareholders - cnhinews.com
Gruve Acquires Lumos Cloud and Forms a Strategic Partnership with Gluware to Redefine AI-Powered Cloud and Network Automation - Yahoo Finance
Hypopituitarism Market Forecasted to Surge in Coming Years, - openPR
Lumos Pharma Inc (LUMO) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Prudence - Investing.com Canada
Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience. - Proactive Investors USA
Lumos Pharma Inc Stock (LUMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):